use of pi3k activity or function inhibitors for the treatment of primary sjögren's syndrome

• 收藏
• 分享

专利权人:

NOVARTIS AG

发明人:

ANDREAS CHRIST,BRUNO BIETH,CHRISTOPH BURKHART,CHRISTOPH KALIS,SAM LINDGREN,STEFAN DE BUCK

申请号：

BR112018015272

公开号：

BR112018015272A2

申请日:

2017.02.10

申请国别(地区):

BR

年份:

2018

代理人:

摘要：

The invention relates to the use of 1 - {(s) -3- [6- (6-methoxy-5-trifluoromethyl-pyridin-3-yl) -5,6,7,8-tetrahydropyrido [ 4,3-d] pyrimidin-4-ylamino] -pyrrolidin-1-yl} -propan-1-one, or pharmaceutically acceptable salts thereof, for the treatment of primary Sjögren's syndrome.a invenção refere-se ao uso de 1-{(s)-3-[6-(6-metóxi-5-trifluorometil-piridin-3-il)-5,6,7,8-tetra-hidro-pirido[4,3-d]pirimidin-4-ilamino]-pirrolidin-1-il}-propan-1-ona, ou sais farmaceuticamente aceitáveis desta, para o tratamento de síndrome de sjögren primária.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/